Bio-Techne, a global life sciences company, agreed to acquire Asuragen, a biotechnology company, for $215m in cash plus contingent consideration of up to $105m upon the achievement of certain future milestones. "Bio-Techne's global presence, reputation and relationships within the clinical diagnostic and research communities will enable Asuragen to broaden our reach and accelerate penetration into the high-growth molecular diagnostic markets addressed by our portfolio. I am honored to continue to lead the Asuragen team as a part of Bio-Techne. I would like to thank all of the great people of Asuragen for their committed efforts growing our company to this point and am looking forward to the next stage of growth under the Bio-Techne umbrella," Matt McManus, Asuragen Chief Executive Officer.